1. 欢 迎 光 临欢 迎 光 临

2. NCCN Clinical Practice Guidelines in Oncology™ Melanoma Lili Yun nan biotherapy center 2008.1.10

3. Overview  In the year 2007, an estimated 59,940 new cases of melanoma will be diagnosed and about 8,110 patients will die of the disease in the United States.  The incidence of melanoma continues to increase dramatically.  The median age at diagnosis is 45 to 55 years.

4.  Risk factors for melanoma include strong family history, pigmented lesions, multiple clinically atypical moles and inherited genetic mutations.  prognostic factors include:  Tumor burden (expressed as the number of positive nodes);  Macroscopic (clinically apparent) or microscopic (clinically occult) nodal involvement;  the presence of extra － nodal soft-tissue extension;  primary tumor ulceration.

9. Management of Metastatic Melanoma  Dacarbazine still remains a standard of care in community practice.  High dose intravenous bolus IL-2 treatment.  Combination chemotherapy regimens such as CVD(dacarbazine plus cisplatin and vinblastine) or Dartmouth regimen (dacarbazine, carmustine, cisplatin and tamoxifen)

10.  Biochemotherapy is the combination of chemotherapy and biological agents. CVD biochemotherapy (cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2)

11. Thank you!